Ansell is a global, Australian-domiciled but operationally US- and Europe-centred leader in personal protective equipment (PPE), focused predominantly on hand protection and, increasingly, body protection for cleanroom, laboratory, chemical and industrial environments. It sells roughly 10 billion gloves a year and claims No. 1 or No. 2 positions in its key global segments. Following the July 2024 acquisition of Kimberly-Clark's PPE business (KBU; Kimtech and KleenGuard brands), Ansell crossed US$2bn in sales and repositioned toward higher-value "scientific" verticals — pharmaceutical, medical-device and semiconductor cleanrooms — alongside its established HyFlex, Ringers, AlphaTec, MICROFLEX, TouchNTuff and GAMMEX franchises. Its model is that of a vertically integrated branded manufacturer: 14 owned plants concentrated in Malaysia, Sri Lanka and Thailand supply differentiated products, while commoditised exam gloves are partly outsourced. Under a new CEO (Feb 2026), strategy now centres on commercial excellence, strategic-market focus, and operational simplification.
---
### Company's own description (FY26 Annual Report)
Ansell describes its principal activities as the design, development, manufacture, sourcing, distribution and sale of a wide range of hand and body protection solutions for the industrial and healthcare markets, operating in two segments, Industrial and Healthcare. It presents itself as "a global leader in safety solutions and an integrated manufacturer of personal protection equipment for healthcare and industrial workplaces," with brands trusted daily by over 10 million workers in more than 100 countries (FY26 ASX release boilerplate).
**Healthcare Segment:** manufactures and markets solutions for hospitals, surgical centres, dental surgeries, veterinary clinics, first responders, manufacturers, auto repair shops, chemical plants, laboratories and life science/pharmaceutical companies. The portfolio comprises surgical gloves and other operating-room consumables; single-use and examination gloves (including single-use gloves for industrial and laboratory applications); and cleanroom products including clean and sterile gloves, garments and consumables.
**Industrial Segment:** manufactures and markets high-performance hand, eye and chemical protective clothing for automotive, chemical, metal fabrication, machinery & equipment, food, construction, mining, oil & gas, utilities, logistics and first-responder end users.
### Business model and revenue model
| Dimension | Characterisation |
|---|---|
| Revenue model | ~100% product sales (consumable PPE). Services (AnsellGUARDIAN safety assessments, RightCycle recycling program) are value-added and not separately monetised in reported revenue (n/d). No subscription or licensing revenue disclosed. |
| Product vs. service mix | Product ≈ 100%; service revenue n/d |
| Manufacturing model | Hybrid: 14 owned plants (largest in Malaysia, Sri Lanka, Thailand; smaller in Brazil, China, Lithuania, Portugal, Vietnam, India) plus third-party sourcing "predominantly exam and single use gloves" (FY26 AR). In FY23, in-house differentiated products exceeded 40% of Exam/SU sales following the Careplus buyout. |
| Go-to-market | Predominantly via distributors (industrial safety distributors, medical/surgical distributors, laboratory/scientific distributors), combined with direct end-user specification ("end user partnerships") — e.g., Amazon warehouse impact-glove program. Only a small proportion of sales (mostly European healthcare) is on price-driven tenders (Morningstar). |
| Pricing power | Demonstrated: full offset of ~US$80m in higher US tariff costs via sourcing and pricing in FY26 (Morningstar estimate of tariff quantum; company confirms full offset), plus Middle East cost-inflation pass-through in H2 FY26. |
| Brand concentration | Top five brands = 58% of total sales, growing 1.2x group rate in FY26 (FY26 AR, CEO Review). |
| Consumable/recurring nature | High: gloves and garments are single-use or short-life consumables; demand tied to employment, hygiene/regulatory standards and production volumes in end markets. |
### Value chain position
Ansell sits in the midstream-to-downstream of the PPE value chain: it buys raw materials (nitrile butadiene latex, natural rubber latex, polyisoprene/neoprene for synthetic surgical gloves, yarns such as HPPE/nylon/rPET for cut-resistant liners, ceramic formers, chemicals, packaging), converts them in owned dipping and knitting plants, and also contracts finished exam gloves from Malaysian/Thai/other OEMs. It adds value through material science (e.g., FORTIX, AEROFIT, INTERCEPT cut technologies; bio-based nitrile), certification and regulatory compliance (FDA 510(k), EU MDR/PPE Regulation, EN 388/EN ISO 374, ASTM D6978 for chemotherapy drugs, ISO 13485), sterilisation and cleanroom processing, and specification-led selling.
### Customer types and end markets
| End-market cluster | Examples | Segment |
|---|---|---|
| Acute healthcare | Hospitals, surgical centres (surgical gloves — GAMMEX, ENCORE, Micro-Touch surgical lines), dental, veterinary | Healthcare |
| Scientific / Life sciences | Pharmaceutical and biotech manufacturing (cleanroom gloves, garments, isolator gloves), laboratories, medical device manufacture, semiconductors | Healthcare (Cleanroom; Exam/SU) |
| Industrial single-use | Automotive repair, chemical plants, food processing, janitorial (MICROFLEX, TouchNTuff) | Healthcare (Exam/SU) |
| Industrial reusable hand protection | Automotive, metal fabrication, machinery, construction, mining, logistics/warehousing (HyFlex, Ringers, ActivArmr, EDGE) | Industrial (Mechanical) |
| Chemical protection | Chemical, oil & gas, pharma, first responders, defence (AlphaTec gloves, suits; KleenGuard body protection) | Industrial (Chemical) |
| Aerospace & defence | Precision cut and chemical hand protection | Industrial (identified FY26 growth vertical) |
### Independent characterisation
Ansell is best understood as a premium, specification-driven consumables franchise operating inside a structurally commoditised category. Commodity exam gloves (dominated by Malaysian and Thai mass producers) set a low-price floor, and Ansell's economic moat lies in the parts of the market where failure costs are high — sterile surgical, cleanroom/isolator, chemotherapy-rated, chemical-resistant and high-cut-level reusable gloves — and where switching requires re-qualification. The KBU acquisition materially deepened exposure to the highest-value niche (scientific cleanroom), and FY26 results show the margin effect: Healthcare Adjusted EBIT margin rose from 12.8% to 14.3%. The residual weakness is that roughly half of Healthcare revenue (Exam/SU) remains exposed to commodity price cycles and outsourced supply, as the FY23–FY24 post-pandemic destocking demonstrated (Healthcare sales fell from ~US$1.19bn in FY22 to US$834m in FY24).